Among the countless molecular transactions that sustain life, few are as consequential — or as easily overlooked — as the quiet, continuous work of DNA repair. Each day, every cell in the human body is subjected to a barrage of chemical insults that introduce errors into its genomic sequence; left unattended, even a single misincorporated or chemically altered nucleotide can precipitate a mutation with potentially catastrophic consequences. One of the enzymes tasked with correcting such errors is human SMUG1 — Single-strand-selective Monofunctional Uracil DNA Glycosylase 1 — a protein long known to play a pivotal role in the base excision repair (BER) pathway, yet whose three-dimensional architecture had, until now, remained entirely unresolved. A study published in June 2026 in Nature Communications by Julian Ludäscher, Pål Stenmark, and colleagues at Stockholm University, Uppsala University, and Karolinska Institutet has filled that gap in remarkable fashion, delivering the first atomic-resolution structures of human SMUG1 in multiple functional states.
The molecular logic of SMUG1’s role begins with an apparent contradiction: uracil, one of the four canonical bases of RNA, has no legitimate place in DNA. When it appears there — whether through the spontaneous deamination of cytosine, through errors of replication, or through the incorporation of the chemotherapy drug 5-fluorouracil (5-FU) — it must be recognized and excised before it can cause a mutation. SMUG1 accomplishes this through a mechanism known as base flipping: the enzyme engages a damaged stretch of double-stranded DNA, induces a local structural distortion that rotates the target base out of the helical stack, and then catalyzes its hydrolytic removal. What the new structures reveal, at atomic resolution achieved by combining X-ray crystallography with neutron diffraction and molecular dynamics simulations, is precisely how this recognition-and-excision choreography unfolds at the level of individual amino acid residues and hydrogen bonds. The team captured SMUG1 in several distinct states — alone, bound to uracil and 5-FU as products, and in complex with double-stranded DNA bearing an abasic site — allowing them to reconstruct the successive stages of the repair cycle and to identify the key residues required for both DNA binding and catalytic activity.
Perhaps the most technically striking achievement of this work is the first combined neutron and X-ray structure of any DNA-binding protein — a methodological advance that grants visibility into proton positions and hydrogen-bonding networks within the enzyme’s active site that X-ray crystallography alone cannot resolve. This level of mechanistic detail carries direct therapeutic relevance, since SMUG1 is implicated in the cellular response to 5-fluorouracil, one of the most widely used chemotherapeutic agents in the treatment of colorectal, breast, and head-and-neck cancers. By excising incorporated 5-FU from DNA, SMUG1 may partially counteract the cytotoxic intent of the drug, contributing to the resistance mechanisms that limit its clinical efficacy. Conversely, inhibitors designed to suppress SMUG1 activity could potentially sensitize tumors to 5-FU-based regimens; alternatively, activators might accelerate the removal of mutagenic uracil in contexts where genomic stability is a priority. The structural data presented here constitute, for the first time, a rational blueprint for both types of intervention.
Nonetheless, several caveats deserve acknowledgment before these perspectives can be projected into clinical strategies. The structures were obtained in the context of isolated protein complexes rather than within the full architecture of the BER pathway, where SMUG1 interacts with downstream partners such as APE1 (apurinic/apyrimidinic endonuclease 1), and it remains unclear how this broader molecular context shapes its activity and selectivity in intact cells. The study also relies primarily on crystallographic snapshots that capture static conformations, and the dynamics of base flipping and product release in the physiological milieu may differ in ways that the current data cannot fully capture. Nevertheless, these limitations do not diminish the significance of what has been achieved: a mechanistically coherent and structurally grounded account of how a central guardian of genomic integrity performs its work, opening a genuinely new chapter in the structural biology of DNA repair and providing a concrete starting point for the drug discovery programs that may ultimately translate this knowledge into clinical benefit.
Leave a Reply